Soluble CD163 as a Potential Biomarker in Systemic Sclerosis

Abstract EN

Objective.

To evaluate the performance of serum and urinary sCD163 concentrations as possible biomarker in systemic sclerosis (SSc).

Methods.

Urine and serum samples were obtained from SSc patients and age- and sex-matched controls.

Serum and urinary sCD163 concentrations were measured by commercially available ELISA kit.

SSc patients were assessed following international guidelines.

Cross-sectional analyses were performed.

Results.

Two hundred and three SSc patients were included.

The control group consisted of 47 age- and sex-matched patients having noninflammatory diseases, mainly osteoporosis.

Serum sCD163 levels were significantly higher in SSc patients compared with controls (mean ± SD: 529 ± 251 versus 385 ± 153 ng/mL; p<0.001).

Urinary sCD163 concentrations were higher in SSc patients than controls, but this did not reach significance (236 ± 498 versus 176 ± 173 ng/mg uCr; p=0.580).

The sCD163 concentrations were not associated with clinical, laboratory, and instrumental characteristics of SSc patients.

Conclusion.

To our knowledge, this is the first evaluation of both serum and urinary sCD163 levels in SSc.

Our results show a significant difference for sera values that should be prioritized for further studies as compared to urinary measurements.

Our results further support that the M2 macrophages/CD163 signaling system may play a role in the pathogenesis of SSc, although we could not identify a subset of SSc patients with higher concentrations.